Regenxbio RGNX reported its Q4 earnings results on Tuesday, February 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Earnings
Regenxbio missed estimated earnings by -13.0%, reporting an EPS of $-1.43 versus an estimate of $-1.27.
Revenue was down $9.13 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.08 which was followed by a 2.0% increase in the share price the next day.
Here's a look at Regenxbio's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -1.49 | -1.26 | -1.54 | -1.23 |
EPS Actual | -1.41 | -1.66 | -1.53 | -1.38 |
Revenue Estimate | 27.19M | 39.83M | 30.60M | 37.45M |
Revenue Actual | 28.91M | 19.98M | 19.14M | 31.34M |
To track all earnings releases for Regenxbio visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.